By optimizing the LGIPCsi formulation for stability, siRNA encapsulation, and selective tumor uptake, we aimed to overcome delivery challenges and assess the therapeutic efficacy of GIPC1 silencing alone or in combination with GEM in orthotopic and patient-derived xenograft models. The gene discussed is GIPC1; the disease is neoplasm.